Clinical analysis of 10 patients with subcutaneous panniculitis-like T cell lymphoma.
10.7534/j.issn.1009-2137.2013.04.022
- Author:
Shu-Hong WANG
1
;
Quan-Shun WANG
;
Lu SUN
;
Hong-Hua LI
;
Yu ZHAO
;
Bo-Jun JIA
;
Jia-Xing TIAN
;
Li YU
Author Information
1. Department of Hematology, the General Hospital of Chinese PLA, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Female;
Humans;
Lymphoma, T-Cell;
drug therapy;
pathology;
Male;
Middle Aged;
Panniculitis;
drug therapy;
pathology;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(4):926-929
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to evaluate the clinical and pathological features, prognosis of patients with subcutaneous panniculitis-time T cell lymphoma (SPTCL). The clinicopathologic features, immunophenotypes and treatment of 10 SPTCL patients which confirmed by pathology were analyzed retrospectively. The results showed that the main clinical manifestations of SPTCL were the single or multiple subcutaneous nodules. Of them 8 cases were found with recurrent high fever, weight loss, injury of liver function, bone marrow involvement and pancytopenia. This disease rapidly advanced. Pathologically, atypical large, medium-size and small-lymphocytes rounded the lipocytes look like rosettes. The reactive proliferation of histiocytes accompanied by phagothrocytic phenomena, polynuclear giant cells and granulomatous reaction. The tumor cells infiltrated into the lipolubuls. This lymphoma expressed the cytotoxic T-cell immunophenotype. CHOP regimen was the most common chemotherapy regimen used. 60% patients achieved a good initial response to chemotherapy. 3-year survival was 10%, with median survival time of 10 months. It is concluded that SPTCL is a specific type of lymphoma involving primarily in subcutaneous fatty tissues, most cases of SPTCL display an aggressive course, the disease may progress rapidly and accompanies with unfavorable prognosis. And the prognosis is poor in SPTCL patients with hemophagocytic syndrome. but the allo-HSCT can improve the outcome of this disease.
